Navigation Links
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
Date:8/6/2008

Dr. Moreadith began his career in the pharmaceutical industry as Principal Medical Officer of Quintiles, Inc., the world's leading pharmaceutical services organization, where he was recruited to build Quintiles' Cardiovascular Therapeutics Group.

Dr. Moreadith has published more than 50 scientific papers and chapters, is an inventor on a number of patents and has received numerous awards for his achievements. He received his M.D. from Duke University and his Ph.D. from Johns Hopkins University, and was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. His faculty appointments include the University of Texas Southwestern Medical Center, where he was an Established Investigator of the American Heart Association.

"I am excited to join Nektar, the industry leader in PEGylation chemistry and pulmonary therapeutics," said Dr. Randall Moreadith. "Nektar's innovative development of therapeutics using its proprietary technologies are among the most important and promising areas in biopharmaceutical drug development. I look forward to building a world-class drug development organization that will advance Nektar's programs rapidly through the clinic."

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

This press release contains forward-looking statements that reflect the company's current views as to its products, development programs, science and technology and business prospects. These forward-looking statements involve
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
9. Nektar Therapeutics Announces First Quarter 2008 Results
10. Prime Therapeutics Receives TIPPS Certification
11. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... Open Tennis Championship tickets in NYC. In just a ... USTA Billie Jean King Tennis Center. The event was originally founded ... the 2013 event, Rafael Nadal was forced to withdrawal from the ... of the 2014 women’s tournament and will return to New York ...
(Date:8/20/2014)... in Australia examined patient and tumor characteristics for ... tumor cell growth) in an effort to increase ... , Author: Sarah Shen, M.B.B.S., ... colleagues. , Background: The tumor characteristic known ... been connected with prognosis and survival in melanoma ...
(Date:8/20/2014)... Opinion: The time to deploy Ebola vaccines is now, ... vaccines is now, according to a commentary being published ... Medicine . The authors from Yale School of ... geographic dissemination of the current Ebola outbreak represent a ... under current efforts. Several Ebola vaccines have been developed ...
(Date:8/20/2014)... of brain cells that act as a "sleep switch" ... and staying asleep, a new study suggests. In ... often results in nighttime confusion and wandering, according to ... Rush Memory and Aging Project, which includes nearly 1,000 ... followed until death, at which point their brains are ...
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:News from Annals of Internal Medicine 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3
... most common breast cancer uses the most efficient, powerful ... that system kills it, researchers report. This method ... patients, particularly those resistant to standard therapies such as ... Human estrogen receptor-positive breast cancer cells thriving in a ...
... The second generation drug-eluting stent, everolimus-eluting stent ... in randomised controlled trials over the first ... earlier studies comparing EES with another first ... only demonstrated the non-inferiority of EES; the ...
... order to meet future demands for new pharmaceuticals, ... is dependent on the ongoing development of effective ... Because they are so versatile, organometallic molecules are ... reagents containing zinc atoms have certain advantages over ...
... , MONDAY, Aug. 29 (HealthDay News) -- Boxing ... encourage their kids to find sports that don,t focus ... Those are conclusions from the new policy statement from ... Society that recommends that pediatricians vigorously oppose children participating ...
... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 386 scientific research sessions, 468 posters, and several ... a unique opportunity for journalists from around the world to ...
... 28 (HealthDay News) -- Although it may sound sweet ... behavior, similar to arguing or slinging insults, Canadian scientists ... Queens University in Kingston, Ontario, also revealed that differences ... live, play a role in how aggressive their shouting ...
Cached Medicine News:Health News:Research aims to starve breast cancer cells 2Health News:Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents 2Health News:New salts for chemical soups 2Health News:Pediatric Groups Want to KO Boxing for Kids 2Health News:Pediatric Groups Want to KO Boxing for Kids 3Health News:2011 AAO-HNSF poster presentations 2Health News:2011 AAO-HNSF poster presentations 3Health News:2011 AAO-HNSF poster presentations 4Health News:2011 AAO-HNSF poster presentations 5Health News:2011 AAO-HNSF poster presentations 6Health News:2011 AAO-HNSF poster presentations 7Health News:2011 AAO-HNSF poster presentations 8Health News:2011 AAO-HNSF poster presentations 9Health News:2011 AAO-HNSF poster presentations 10Health News:2011 AAO-HNSF poster presentations 11Health News:2011 AAO-HNSF poster presentations 12Health News:2011 AAO-HNSF poster presentations 13Health News:2011 AAO-HNSF poster presentations 14Health News:2011 AAO-HNSF poster presentations 15Health News:2011 AAO-HNSF poster presentations 16Health News:2011 AAO-HNSF poster presentations 17Health News:2011 AAO-HNSF poster presentations 18Health News:2011 AAO-HNSF poster presentations 19Health News:2011 AAO-HNSF poster presentations 20Health News:2011 AAO-HNSF poster presentations 21Health News:Sweet Sparrow Songs May Actually Be Shouting Matches 2
(Date:8/20/2014)... 20, 2014 The National Necrotizing Fasciitis Foundation (NNFF) ... has been successfully treated for a life threatening form of ... R. Gauto , Medical Director of Inpatient Wound Care and ... in Rancho Mirage, California . ... John Crew at Seton Hospital in ...
(Date:8/20/2014)... -- Research and Markets has announced ... Care and Closure Market (Types, Applications, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. The new report ... (types, applications, end user and geography) - Size, ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... , , , , TEL ... - StemEx Study is Enrolling Patients at Cord Blood Transplant Centers in,the U.S., ... , Elbit Imaging Ltd. (NASDAQ: EMITF ) ("Elbit" ... Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV),announced today that the ...
... , , SAN DIEGO , ... a leading, global medical device company, today reported results from continuing ... 2009 . , "We continued to execute well during our ... Schlotterbeck , chairman and CEO of CareFusion. "Hospital capital spending made ...
Cached Medicine Technology:Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 4Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 5CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: